Breast cancer vaccines: a clinical reality or fairy tale? (Q30351838)

20 June 2017

1 reference

title

Breast cancer vaccines: a clinical reality or fairy tale? (English)

1 reference

20 June 2017

1 reference

G Curigliano

1

1 reference

20 June 2017

G Spitaleri

2

1 reference

20 June 2017

E Pietri

3

1 reference

20 June 2017

M Rescigno

4

1 reference

20 June 2017

F de Braud

5

1 reference

20 June 2017

A Cardillo

6

1 reference

20 June 2017

E Munzone

7

1 reference

20 June 2017

A Rocca

8

1 reference

20 June 2017

G Bonizzi

9

1 reference

20 June 2017

V Brichard

10

1 reference

20 June 2017

L Orlando

11

1 reference

20 June 2017

A Goldhirsch

12

1 reference

20 June 2017

publication date

17 November 2005

1 reference

20 June 2017

1 reference

20 June 2017

volume

17

1 reference

20 June 2017

issue

5

1 reference

20 June 2017

page(s)

750-762

1 reference

Monoclonal antibodies, small molecules, and vaccines in the treatment of breast cancer

20 June 2017

cites work

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDJ083

Overview of therapeutic vaccination approaches for cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDJ083

Candidate epitope identification using peptide property models: application to cancer immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDJ083

Immunotherapy of cancer: from vision to standard clinical practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDJ083

Quantitating cellular immune responses to cancer vaccines.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDJ083

Immunobiology of HER-2/neu oncoprotein and its potential application in cancer immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDJ083

Human HER-2/neu protein immunization circumvents tolerance to rat neu: a vaccine strategy for 'self' tumour antigens

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDJ083

Immunization with a HER-2/neu helper peptide vaccine generates HER-2/neu CD8 T-cell immunity in cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDJ083

Effect of dose on immune response in patients vaccinated with an her-2/neu intracellular domain protein--based vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDJ083

Tumor-specific immunity in MUC1.Tg mice induced by immunization with peptide vaccines from the cytoplasmic tail of CD227 (MUC1).

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDJ083

Immunogenicity of synthetic peptides related to the core peptide sequence encoded by the human MUC1 mucin gene: effect of immunization on the growth of murine mammary adenocarcinoma cells transfected with the human MUC1 gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDJ083

Anti-MUC1 class I restricted CTLs in metastatic breast cancer patients immunized with a synthetic MUC1 peptide

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDJ083

Oxidative/reductive conjugation of mannan to antigen selects for T1 or T2 immune responses.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDJ083

Antibody and T cell responses of patients with adenocarcinoma immunized with mannan-MUC1 fusion protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDJ083

Carcinoembryonic antigen-based vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDJ083

Diversified prime and boost protocols using recombinant vaccinia virus and recombinant non-replicating avian pox virus to enhance T-cell immunity and antitumor responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDJ083

Phase I study in advanced cancer patients of a diversified prime-and-boost vaccination protocol using recombinant vaccinia virus and recombinant nonreplicating avipox virus to elicit anti-carcinoembryonic antigen immune responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDJ083

Cancer vaccines based on the identification of genes encoding cancer regression antigens

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDJ083

Phase I study of sequential vaccinations with fowlpox-CEA(6D)-TRICOM alone and sequentially with vaccinia-CEA(6D)-TRICOM, with and without granulocyte-macrophage colony-stimulating factor, in patients with carcinoembryonic antigen-expressing carcino

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDJ083

Induction of cytotoxic T cell responses and tumor immunity against unrelated tumors using telomerase reverse transcriptase RNA transfected dendritic cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDJ083

Telomerase as a universal tumor-associated antigen for cancer immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDJ083

Vaccination of cancer patients against telomerase induces functional antitumor CD8+ T lymphocytes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDJ083

A randomised phase II study of sialyl-Tn and DETOX-B adjuvant with or without cyclophosphamide pretreatment for the active specific immunotherapy of breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDJ083

Somatic mutations in the p53 gene and prognosis in breast cancer: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDJ083

Vaccination with p53-peptide-pulsed dendritic cells, of patients with advanced breast cancer: report from a phase I study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDJ083

Viral oncolysates in patients with advanced ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDJ083

Tumor-cell number and viability as quality and efficacy parameters of autologous virus-modified cancer vaccines in patients with breast or ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDJ083

Successful culture and selection of cytokine gene-modified human dermal fibroblasts for the biologic therapy of patients with cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDJ083

Experimental and clinical studies of cytokine gene-modified tumor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDJ083

Identification of tumor-specific antibodies in patients with breast cancer vaccinated with gene-modified allogeneic tumor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDJ083

Inflammatory breast cancer: 10-year follow-up of a trial of surgery, chemotherapy, and allogeneic tumor cell/BCG immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDJ083

Adjuvant autologous renal tumour cell vaccine and risk of tumour progression in patients with renal-cell carcinoma after radical nephrectomy: phase III, randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDJ083

Dendritic cell-based cancer immunotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDJ083

Vaccination by genetically modified dendritic cells expressing a truncated neu oncogene prevents development of breast cancer in transgenic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDJ083

Induction of ErbB-2/neu-specific protective and therapeutic antitumor immunity using genetically modified dendritic cells: enhanced efficacy by cotransduction of gene encoding IL-12.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDJ083

Breast and ovarian cancer-specific cytotoxic T lymphocytes recognize the same HER2/neu-derived peptide

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDJ083

Altered peptide ligand vaccination with Flt3 ligand expanded dendritic cells for tumor immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDJ083

Immunization of metastatic breast cancer patients with a fully synthetic globo H conjugate: a phase I trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDJ083

Therapy with cultured T cells: principles revisited

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDJ083

Characterization of circulating T cells specific for tumor-associated antigens in melanoma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDJ083

Part I: Vaccines for solid tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDJ083

Cancer immunotherapy: moving beyond current vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDJ083

Melanoma-restricted genes

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDJ083

Control of autoimmunity by naturally arising regulatory CD4+ T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDJ083

Control of T-cell activation by CD4+ CD25+ suppressor T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDJ083

Prolongation of survival in metastatic melanoma after active specific immunotherapy with a new polyvalent melanoma vaccine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDJ083

Cell-mediated immune responses to MUC1 fusion protein coupled to mannan

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDJ083

21 January 2018

Identifiers

DOI

10.1093/ANNONC/MDJ083

1 reference

20 June 2017

1 reference